Work

An Anti-cytokine Agent for Anhedonia: Investigating the Immune-inflammatory System as a Therapeutic Target for Dimensional Disturbances in Mood Disorders

Year: 2021
Type: dissertation
Abstract: Patients with depression are conventionally treated with the assumption that a treatment will be broadly effective across multiple dimensions. However, depression is a heterogeneous clinical syndrome that is subserved by multiple convergent and divergent disease processes. Data-driven and ecologically valid phenotypes of phenomenology are needed to parse the heterogenous etiology of depression. Moreover, mechanism-of-action studies should target domain-based pathology with mechanistically plausible treatments and aim to inform disease models.The thesis herein investigated the immune system as a putative therapeutic target for anhedonia, a transdiagnostic, yet specific, and clinically relevant symptom dimension. Anhedonia represents a disturbance in reward- and motivation-related neurobiological processes and is characterized by a diminished ability to enjoy previously enjoyable activities. Brain circuits, nodes, and networks, as well as cellular and molecular pathways (eg dopaminergic transmission, excitotoxicity, synaptic plasticity), subserving anhedonia are preferentially affected by inflammatory processes. Hitherto, no curative treatments have been identified or developed for the treatment of anhedonia. Infliximab, an anti-inflammatory agent that specifically targets tumour necrosis factor-α signalling, reduced anhedonic symptoms in a randomized, double-blinded, placebo-controlled clinical trial. Furthermore, we identified a data-driven inflammatory biotype of adults with bipolar depression who were more likely to derive anti-anhedonic benefit from infliximab. We provide a framework for conceptualizing the therapeutic and mechanistic relevance of the TNF-α signalling pathways in the treatment of anhedonia. Taken together, our findings instantiate the relevance of inflammatory processes and the immune system in the phenomenology and etiology of mood disorders and provide the impetus to develop scalable treatments targeting the immune system to mitigate transdiagnostic, dimensional disturbances (eg anhedonia). A domain-based approach to drug discovery and development, informed by an understanding of disease processes, is needed to target brain-based pathology. Future studies investigating viable anti-anhedonic treatment avenues should demonstrate target engagement in neural systems subserving reward learning and valuation (eg cognition, habit formation), as well as reward-motivated behaviours (eg seeking, consummatory).
Author: Lee, Yena
Language: English
Open Access status: green
OpenAlex ID: W7045471415
Cites: 333
Cited by:
Related to: 10